<div class="container">

<table style="width: 100%;"><tr>
<td>statin101</td>
<td style="text-align: right;">R Documentation</td>
</tr></table>
<h2>FDA statin dataset with 101 adverse events</h2>

<h3>Description</h3>

<p>A 102 by 5 data matrix of a contingency table processed from
the FDA Adverse Event Reporting System (FAERS) database from Q1 2021 to
Q4 2023.
</p>


<h3>Usage</h3>

<pre><code class="language-R">statin101
</code></pre>


<h3>Format</h3>

<p>A data matrix with 102 rows and 5 columns.
</p>


<h3>Details</h3>

<p>A 102 by data matrix of a contingency table from the FDA Adverse
Event Reporting System (FAERS) database, covering Q1 2021 to Q4 2023.
</p>
<p>The 101 rows correspond to the AEs with the highest overall
frequency (row marginals) reported during the period. The reported AEs -
"Off label use" and "Drug ineffective" have been excluded.
</p>
<p>The 5 columns include 4 statin medications and an "other" column.
Marginal totals for each drug: 101,462 for Atorvastatin, 9,203 for
Fluvastatin, 130,994 for Rosuvastatin,
87,841 for Simvastatin, and 57,393,834 for Other drugs.
</p>
<p>Also refer to supplementary material of:
</p>
<p>Ding, Y., Markatou, M., &amp; Ball, R. (2020). An evaluation of statistical
approaches to postmarketing surveillance. Statistics in Medicine, 39(7),
845-874
</p>
<p>for the data generation process.
The quarterly files can be found in
<a href="https://fis.fda.gov/extensions/FPD-QDE-FAERS/FPD-QDE-FAERS.html">https://fis.fda.gov/extensions/FPD-QDE-FAERS/FPD-QDE-FAERS.html</a>.
</p>


<h3>Examples</h3>

<pre><code class="language-R">data(statin101)
head(statin101)

</code></pre>


</div>